Protein Target for Prostate Cancers

Tech ID: 27251 / UC Case 2015-539-0

Abstract

Researchers at the University of California, Davis have identified a unique protein target for the development of therapies for advanced prostate cancers.

Full Description

There is a strong need for the development of therapies for the treatment of advanced prostate cancers (PCa). Current therapeutics target either the androgen receptor (AR) or the androgen biosynthesis enzymes. These treatments are subject to cancer resistance and together give only a few months of overall survival benefit in a portion of PCa patients.

Researchers at the University of California, Davis, have identified a unique protein target, ROR-γ, for the development of effective PCa therapeutics. By targeting ROR-γ, two important PCa tumor-driving pathways are inhibited. The inhibitors have been synthesized and verified in vitro in PCa cells and in vivo in xenograft mouse model with human PCa.This mechanism of action (MOA) has the potential to be an effective target for therapy resistant cancers and offers an improved therapeutic approach compared to currently available therapies.

Applications

  • Small molecule inhibitors
  • siRNA silencing

Features/Benefits

  • Unique, druggable target
  • Novel mechanism of action

Related Materials

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20180085348 03/29/2018 2015-539
Patent Cooperation Treaty Published Application 2016145298A1 09/15/2016 2015-539
 

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Chen, Hongwu
  • Wang, Junjian (Jack)
  • Zou, June X.

Other Information

Keywords

ROR-gamma, mechanism of action, advanced prostate cancers

Categorized As

Additional Technologies by these Inventors